A5034238873- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Immune Cell Function and Interaction
- Pneumonia and Respiratory Infections
- T-cell and B-cell Immunology
- COVID-19 and healthcare impacts
- Infectious Encephalopathies and Encephalitis
- Thermal Regulation in Medicine
- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
- Health Systems, Economic Evaluations, Quality of Life
- Adolescent and Pediatric Healthcare
- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Immunotherapy and Immune Responses
- Child and Adolescent Health
- Global Health Care Issues
- Gastroesophageal reflux and treatments
- Emergency and Acute Care Studies
- Hepatitis C virus research
- Respiratory viral infections research
- Primary Care and Health Outcomes
- Healthcare Policy and Management
- Business Strategy and Innovation
- Vitamin D Research Studies
Pfizer (United States)
2023-2025
Pfizer (United Kingdom)
2022-2025
Public Health England
2015-2021
Imperial College London
2015-2021
NIHR Imperial Biomedical Research Centre
2021
Utrecht University
2011-2017
Medical Research Council
2015
Altrecht GGZ
2011
University of Cape Town
2006
Despite the current pneumococcal vaccination program in England for older adults and with underlying conditions, disease burden remains high. We evaluated cost-effectiveness of 20-valent conjugate vaccine (PCV20) compared to recommendations England.Lifetime outcomes/costs invasive (IPD) community-acquired pneumonia (CAP) among aged 65-99 years 18-64 conditions were projected using a deterministic cohort model. Vaccination PCV20 was 23-valent polysaccharide (PPV23) from National Health...
Background: Nirmatrelvir/ritonavir (NMV/r) and molnupiravir are oral antiviral drugs approved for the treatment of early symptomatic patients with mild to moderate COVID-19 at high risk progression severe disease in Japan. Objective: This study evaluated, from a Japanese payer perspective, cost-effectiveness NMV/r compared among COVID-19. Methods: model describes history impact on short-term long-term outcomes. was molnupiravir, scenario analysis standard care over lifetime horizon. Results:...
Background: Nirmatrelvir/ritonavir (NMV/r) and molnupiravir are oral antiviral drugs approved for the treatment of early symptomatic patients with mild to moderate COVID-19 at high risk progression severe disease in Japan. Objective: This study evaluated, from a Japanese payer perspective, cost-effectiveness NMV/r compared among COVID-19. Methods: model describes history impact on short-term long-term outcomes. was molnupiravir, scenario analysis standard care over lifetime horizon. Results:...
The objective was to estimate the cost-effectiveness of nirmatrelvir/ritonavir (NMV/r) in treating adults with COVID-19 at high-risk developing severe who do not require supplemental oxygen, compared no treatment, from Spanish National Health System (NHS) perspective. A decision-tree for first year followed by a two-state Markov model annual cycles lifetime horizon developed. cohort 1000 high-risk, symptomatic patients entered each comparator, divided into hospitalized patients, considering...
Nirmatrelvir/ritonavir (NMV/r) is an orally administered antiviral indicated for the outpatient treatment of patients with mild-to-moderate COVID-19 at high risk disease progression to severe illness. We estimated cost-effectiveness NMV/r versus best supportive care illness from a US health sector perspective.
Accurate and up-to-date figures of the cost community-acquired pneumonia (CAP) hospitalization are needed to understand associated economic burden for public health decision-makers. Recent estimates lacking, previously published differ markedly. Our objective was estimate current mean UK National Health Service (NHS) adult hospitalized CAP.All CAP hospitalizations in 2019 those aged ≥18 years were identified from English Hospital Episode Statistics (HES). Each mapped tariff paid care...
Background Despite progress in TB control low-burden countries like England and Wales, there are still diagnostic delays. Molecular testing and/or whole-genome sequencing (WGS) provide more rapid diagnosis but their cost-effectiveness is relatively unexplored settings. Methods An integrated transmission-dynamic health economic model used to assess the of using WGS replace culture-based drug-sensitivity testing, versus molecular combined use for routine diagnosis. The accounts effects faster...
To quantify direct costs and healthcare resource utilisation (HCRU) associated with acute COVID-19 in adults England.
Background: In HIV infection, the homeostasis of CD4+ and CD8+ T cells is dramatically disturbed, several studies have pointed out that T-cell turnover rates are increased. To understand how pools affected, it important to quantitative insights into lifespans constituting different T-lymphocyte populations. Methods: We used long-term in-vivo 2H2O labeling mathematical modeling estimate average naive memory in untreated (n = 4) combination antiretroviral therapy-treated 3) HIV-1-infected...
The peripheral naive T-cell pool is generally thought to consist of a subpopulation recent thymic emigrants (RTE) and mature (MN) T cells with different dynamics. Thymus transplantation adoptive transfer studies in mice have provided contradicting results, some suggesting that RTE are relatively short-lived cells, while another study suggested survival advantage. We here estimate the death rates MN by performing both thymus transplantations deuterium labeling experiments at least 12 weeks...
Naive T cells in untreated HIV-1 infected individuals have a reduced T-cell receptor excision circle (TREC) content. Previous mathematical models suggested that this is due to increased naive division. It remains unclear, however, how TREC contents can be reconciled with gradual loss of infection. We performed longitudinal analyses humans before and after seroconversion, used model investigate which processes could explain the observed changes numbers TRECs during disease progression. Both...
Background Despite use of 23-valent pneumococcal polysaccharide vaccine (PPV23) in England, disease burden among at-risk adults remains high. We evaluated the public health and budgetary impact 20-valent conjugate (PCV20) compared to current adult vaccination program.Methods Five-year outcomes costs invasive (IPD) community-acquired pneumonia (CAP) aged 65–99 years 18–64 with underlying conditions England were projected using a deterministic cohort model. Hypothetical PCV20 versus PPV23 was...
Abstract Homeless persons have elevated risk of tuberculosis (TB) and are under-served by conventional health services. Approaches to active case-finding (ACF) treatment tailored their needs required. A transmission-dynamic model was developed assess the effectiveness efficiency screening with mobile Chest X-ray, GeneXpert, or both. Effectiveness ACF depends upon prevalence infection in population (which determines ‘yield’), patient willingness wait for GeneXpert results, adherence. is...
ABSTRACT Objectives To quantify healthcare resource utilisation (HCRU) and costs to the National Health Service (NHS) associated with acute COVID-19 in adults England. Design Population-based retrospective cohort study, using Clinical Practice Research Datalink (CPRD) Aurum primary care electronic medical records linked when available Hospital Episode Statistics (HES) secondary administrative data. Setting Patients registered practices Population 1,706,368 a positive SARS-CoV-2 PCR or...
BACKGROUND: Nirmatrelvir/ritonavir (NMV/r) is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk progression to severe COVID-19. NMV/r has also been authorized emergency use by US Food and Drug Administration pediatric patients (aged 226512 years weighing least 40 kg) Understanding budget impact introducing with key interest payers. OBJECTIVE: To estimate annual a commercial health plan setting current Omicron era. METHODS: A model was developed assess on...
Aims Nirmatrelvir/ritonavir (NMV/r) is an orally administered antiviral indicated for the outpatient treatment of adult patients with mild-to-moderate COVID-19 at high risk disease progression to severe illness. We estimated cost-effectiveness NMV/r versus best supportive care 54 patient cohorts, specified according age, vaccination status and comorbidity burden.
In Japan, medical expenses for COVID-19 treatment transitioned from full public funding support to out-of-pocket (OOP) payment by patients plus partial in October 2023, and fully ended March 2024. This study evaluated the clinical economic impacts of initiating OOP payments.
Despite the observed clinical benefits of nirmatrelvir/ritonavir (NMV/r), it is uncertain whether Taiwan will continue covering NMV/r for high-risk individuals with mild-to-moderate coronavirus disease 2019 (COVID-19). This analysis assessed impact sustained utilization on COVID-19-associated healthcare resource (HCRU) and mortality from Taiwanese health authority perspective (THAP). A decision tree model estimated incremental number events associated over a 30-day period. Model results...